<DOC>
	<DOC>NCT00654459</DOC>
	<brief_summary>Some nutraceuticals are often advised for their lipid lowering effects. Although many clinical trials have been conducted to assess their efficacy many doubts remain whether they could be considered an effective alternative to statins therapy. The aim of this study was to evaluate the lipid lowering effects and the improvement of endothelial dysfunction in patients with hyperlipidemia, treated with a nutraceutical product (Armolipid Plus)</brief_summary>
	<brief_title>Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Policosanol</mesh_term>
	<criteria>Males and females aged between 18 and 70 Total cholesterol levels &gt; 220 mg/dl and LDLCholesterol &gt; 130 mg/dl; Patients with concomitant pathology such as diabetes, chronic heart failure, coronary artery disease, arterial hypertension, dysthyroidism, were admitted as long as stable in the previous three months Proven intolerance to an Armolipid Plus compound Pregnant women, and women planning to conceive Patients in therapy with lipid lowering drugs within the previous 6 weeks Triglycerides concentration &gt; 500mg/dl were excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>